The NIDA-funded investigation will delve into the health-related repercussions of Arkansas’ medical cannabis program, which was initially approved by voters back in 2016. The state has over 79,000 active medical marijuana ID cardholders who, reports show, have purchased more than 60,000 pounds of medical cannabis—equivalent to $400 million in transactions—since the first dispensary opened its doors in May 2019.
ACHI identifies itself as a sovereign health policy center that was formed in 1998. The nonpartisan center’s primary aim is to enhance Arkansans’ health by providing them with cooperative program development, evidence-rooted research, and social matter advocacy.
A Deep Dive Into Cannabis Consumer Data
In order to understand how medical cannabis legalization has had an impact on consumer medical care in Arkansas, the researchers will merge qualifying consumers’ cannabis purchase data with information pulled from insurance claims records, among other data sources. The study will also explore the effects of the ongoing COVID-19 pandemic on the state’s program.
“This is an exciting and unique opportunity for not only our state, but also the country, to investigate the effectiveness of cannabis for therapeutic use,” said the president and CEO of ACHI, Dr. Joe Thompson. “While researchers have gathered scientific evidence on the use of cannabis for the alleviation of symptoms such as pain and anxiety, there is little evidence on how the amount, strain, potency, and method of use affect a person’s health experience.”
Thompson also serves as the study’s co-principal investigator. He will be joined by another co-principal investigator, Teresa J. Hudson, Ph.D., Pharm.D. Hudson is acknowledged as director of the Division of Health Services Research at UAMS and also maintains a position as an associate director at the VA Health Services Research and Development Center for Mental Healthcare and Outcomes Research.
A total of six data sources will be analyzed for the study, including the Arkansas Healthcare Transparency Initiative’s Arkansas All-Payer Claims Database (APCD). “The APCD is a dynamic tool that promotes transparency in healthcare data, and by combining these datasets, our state can assess specific health outcomes, including inpatient and outpatient care visits, emergency visits, opioid usage and new health diagnosis,” explained commissioner for the Arkansas Insurance Department, Alan McClain.
McClain’s department provides oversight for the Arkansas Healthcare Transparency Initiative, which supports the APCD project. According to the investigators who’ve been tasked with carrying out this study, each of the following additional sources will also ensure a more comprehensive analysis:
Medical marijuana dispensary purchase documents
Vital patient records
Emergency room records
Arkansas State Police motor vehicle crash analysis
Arkansas Department of Health medical marijuana patient enrollment data
Rising Tax Revenue From Arkansas’ Medical Cannabis Sales
The state of Arkansas has raked in almost $50 million in tax revenue from medical marijuana sales since the market got into full swing in mid-2019. Of that amount, $25 million was accrued during the last nine months alone. Based on the existing law, all medical cannabis sold at the state’s licensed dispensaries is taxed at 10.5%. Of that, 4% privilege tax is provided to UAMS for the formation of a national cancer institute.
“If you walk into a dispensary and spend $100, you’ll spend $10.50 additionally in state taxes,” said Scott Hardin, who is a member of the Arkansas Medical Marijuana Commission team. He noted that the industry has been going from strength to strength during the coronavirus pandemic. “Those two taxes, we’ve collected just under $50,000,000, 49.6 million to be specific.”
The Arkansas Department of Health issued Executive Orders 20-06 and 20-16 that temporarily allowed the use of telehealth for medical cannabis certifications amid the COVID-19 pandemic. However, those orders ended on March 31, 2021. Since April 1, 2021, physicians have been forbidden from distributing medical marijuana recommendations based on an assessment conducted through telemedicine. Should this change again in the future, the state might see even higher cannabis tax revenue.
Blunts: What are they exactly, and how do they affect your body? If you’re interested in smoking blunts—or already smoke them—this guide is for you. We’ll cover everything you need to know about this popular cannabis intake method, including how they’re made, how they differ from spliffs and joints, risks of use, and alternative intake…
“Stoned,” “high,” “tripping,” and “baked,” are all terms engrained in the cannabis community. These metaphorical descriptions contribute to how we perceive, interpret, and learn from the experiences produced by cannabis consumption. Cannabis experiences, of course, are unique and highly variable. Specific plant strains, the presence of other cannabinoids, different delivery methods, and a user’s individual…
Thanks to the growing wave of legalization, more consumers than ever can grow their own cannabis right at home. Growing essentials that used to be secretive are now bought and sold freely. This includes items, like grow tents, nutrients, LED lighting, HPS lighting, ventilation, and more. Keeping all these items straight is hard enough, but…
Skin diseases plague millions of individuals, inflicting both physical discomforts in addition to mental and social stress. Thankfully, there is no shortage of skin treatment options available on the market. That said, this established market may soon be in for a major shake-up if recent cannabis research is any indication. Traditionally, cannabis research focused on studying…
As more states move toward legalization, accurately detecting impaired driving is of the utmost importance. Field Sobriety Tests (FSTs) have long been the go-to method for law enforcement to assess driver impairment caused by substances like alcohol. However, a recent 2023 study published in JAMA Psychiatry raises serious questions about the accuracy of these tests…
The statements made regarding cannabis products on this website have not been evaluated by the Food and Drug Administration (FDA). Cannabis is not an FDA-approved substance and is still illegal under federal law. The information provided on this website is intended for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It is not intended as medical advice and should not be considered as a substitute for advice from a healthcare professional. We strongly recommend that you consult with a physician or other qualified healthcare provider before using any cannabis products. The use of any information provided on this website is solely at your own risk.